ZAI Lab (Shanghai) Co., Ltd.
- Country
- 🇨🇳China
- Ownership
- Private, Subsidiary
- Established
- 2014-01-06
- Employees
- -
- Market Cap
- -
- Website
- http://www.zailaboratory.com
A Trial of ZL-1201 in Subjects With Advanced Cancer
- First Posted Date
- 2020-02-06
- Last Posted Date
- 2023-08-22
- Lead Sponsor
- Zai Lab (Shanghai) Co., Ltd.
- Target Recruit Count
- 37
- Registration Number
- NCT04257617
- Locations
- 🇺🇸
US2004, Phoenix, Arizona, United States
🇺🇸US2005, Jacksonville, Florida, United States
🇺🇸US2001, Rochester, Minnesota, United States
MGD013 Monotherapy and Combination With Brivanib Dose Escalation and Expansion Study in Advanced Liver Cancer Patients
- Conditions
- Advanced Hepatocellular Carcinoma (HCC)
- Interventions
- Drug: MGD013 monotherapyDrug: MGD013 in combination with Brivanib Alaninate
- First Posted Date
- 2019-12-26
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Zai Lab (Shanghai) Co., Ltd.
- Target Recruit Count
- 89
- Registration Number
- NCT04212221
- Locations
- 🇨🇳
Prince of Wales Hospital, Hong Kong, Hong Kong, China
A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior Treatment
- Conditions
- Gastric CancerTriple Negative Breast CancerBiliary Tract CarcinomaEndometrial Carcinoma
- Interventions
- First Posted Date
- 2019-11-26
- Last Posted Date
- 2022-06-01
- Lead Sponsor
- Zai Lab (Shanghai) Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT04178460
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, China
🇨🇳Sun Yat-Sen University Cancer Center, Guangzhou, China
🇨🇳Henan Cancer Hospital, Zhengzhou, Henan, China
A Study of ZL-2306 (Niraparib) as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer
- Conditions
- Ovarian Cancer
- Interventions
- Drug: ZL-2306 (Nirapairb)Drug: Placebo Comparator
- First Posted Date
- 2018-10-17
- Last Posted Date
- 2021-06-02
- Lead Sponsor
- Zai Lab (Shanghai) Co., Ltd.
- Target Recruit Count
- 384
- Registration Number
- NCT03709316
- Locations
- 🇨🇳
Anhui Provincal Hospital, Hefei, Anhui, China
🇨🇳Chongqing Cancer Hospital, Chongqing, Chongqing, China
🇨🇳Fujian Cancer Hospital, Fuzhou, Fujian, China
Clinical Trial Evaluating the Efficacy and Safety of ZL-2306 (Niraparib) in Ovarian Cancer Patient
- Conditions
- Platinum-sensitive Relapsed Ovarian Cancer
- Interventions
- Drug: PlacebosDrug: ZL-2306(nirapairb)
- First Posted Date
- 2018-10-15
- Last Posted Date
- 2023-04-13
- Lead Sponsor
- Zai Lab (Shanghai) Co., Ltd.
- Target Recruit Count
- 265
- Registration Number
- NCT03705156
- Locations
- 🇨🇳
Cancer center of Guangzhou medical university, Guangzhou, Guangdong, China
🇨🇳Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳Harbin Medical university cancer hospital, Harbin, Heilongjiang, China
The Clinical Trial to Evaluate the Pharmacokinetics, Safety and Tolerability of ZL-2306 (Niraparib) in Patients With Ovarian Cancer
- Conditions
- Ovarian Cancer
- Interventions
- Drug: ZL-2306 (niraparib)
- First Posted Date
- 2018-06-11
- Last Posted Date
- 2019-01-24
- Lead Sponsor
- Zai Lab (Shanghai) Co., Ltd.
- Target Recruit Count
- 42
- Registration Number
- NCT03551171
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳Haerbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
A Study of Niraparib as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer
- Conditions
- Extensive-stage Small Cell Lung Cancer
- Interventions
- Drug: ZL-2306(nirapairb)Drug: Placebo
- First Posted Date
- 2018-05-04
- Last Posted Date
- 2020-12-21
- Lead Sponsor
- Zai Lab (Shanghai) Co., Ltd.
- Target Recruit Count
- 185
- Registration Number
- NCT03516084
- Locations
- 🇨🇳
Anhui Provincal Hospital, Hefei, Anhui, China
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Beijing Chest Hospital, Capital Medical University, Beijing, Beijing, China
A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC
- Conditions
- Hepatocellular Carcinoma (HCC)
- Interventions
- First Posted Date
- 2018-05-04
- Last Posted Date
- 2019-09-04
- Lead Sponsor
- Zai Lab (Shanghai) Co., Ltd.
- Target Recruit Count
- 90
- Registration Number
- NCT03516071
- Locations
- 🇨🇳
Anhui Provincial Hospital, Hefei, Anhui, China
🇨🇳Nanfang Hospital, Guangzhou, Guangdong, China
🇨🇳Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China